Subscribe to Newsletter
Subspecialties Oncology, Genetics and epigenetics, Biochemistry and molecular biology, Technology and innovation

Validating a targeted NGS approach for molecular characterization of gliomas

sponsored by QIAGEN

Available On-Demand

Targeted NGS has been instrumental in driving our understanding of disease, mainly because it reduces costs per sample, enables the detection of low frequency variants and allows for content customization. Manually designing targeted NGS panels is time- and resource- consuming, but QIAGEN’s primer design algorithms streamline and simplify the process, to deliver the highest possible design coverage. A case study on custom DNA glioma panels will be discussed for clinical research applications in order to molecular classify glioblastomas and the stem cells isolated in 4 molecular subclasses following validation in a clinical research setting to improve results in the molecular definition of gliomas according to WHO classification.

Learning Objectives

  • How to approach customer panel design entering your own content, such as genes or genomic coordinates
  • Elements required to overcome challenges of tumor profiling
  • Validating a custom DNA panel from research to molecular definition of gliomas

Available On-Demand

Visit our Webinar Hub

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine